About this Research Topic
Chronic infection by Human T-lymphotropic virus type 1 (HTLV-1) and Epstein-Barr virus (EBV) causes an immune dysregulation that may culminate in malignant, inflammatory, and infectious disorders in different organs.
HTLV-1 is a deltaretrovirus endemic in Japan, the Caribbean, sub-Saharan Africa, South America, Australo-Melanesia, and foci in the Middle East. HTLV-1 infects CD4+ T-cells, and it is associated with the development of adult T-cell leukemia/lymphoma, HTLV-1-associated myelopathy/tropical spastic paraparesis, infective dermatitis, and disseminated strongyloidiasis. With increasing migration, HTLV-1-associated diseases have been reported in non-endemic countries.
EBV is a herpesvirus that infects B-cells and, occasionally, T or NK-cells. It has a worldwide distribution and is associated with lymphoproliferative diseases (Burkitt's lymphoma, Hodgkin's disease, non-Hodgkin lymphoma, extranodal NK/T-cell lymphoma, post-transplant lymphoproliferative diseases), nasopharyngeal carcinoma, hydroa vacciniforme, chronic active EBV disease, and many other conditions. Some of these disorders are reported especially in Asian and Latin-American populations, suggesting a genetic susceptibility to these diseases.
This Research Topic aims to explore the diverse manifestations of HTLV-1 and EBV-associated disorders focusing on the pathogenesis, clinical manifestations, and treatments. This topic will enlighten the mechanisms of interaction between HTLV-1 and EBV with the host immune system, the clinical features observed in infected patients, and will give an overview of the up-to-date treatments available and under development for these disorders.
Type of manuscript: original research or review articles
Topics may include but are not limited to:
- Epidemiology of HTLV-1 and EBV-associated disorders
- Pathogenesis of adult T-cell leukemia/lymphoma, HTLV-1-associated myelopathy/Tropical
spastic paraparesis, and infective dermatitis
- Clinical manifestations, treatments, and prognostic characteristics of ATLL
- Cost-effectiveness of HTLV-1 prevention in endemic countries
HTLV-1 is a deltaretrovirus endemic in Japan, the Caribbean, sub-Saharan Africa, South America, Australo-Melanesia, and foci in the Middle East. HTLV-1 infects CD4+ T-cells, and it is associated with the development of adult T-cell leukemia/lymphoma, HTLV-1-associated myelopathy/tropical spastic paraparesis, infective dermatitis, and disseminated strongyloidiasis. With increasing migration, HTLV-1-associated diseases have been reported in non-endemic countries.
EBV is a herpesvirus that infects B-cells and, occasionally, T or NK-cells. It has a worldwide distribution and is associated with lymphoproliferative diseases (Burkitt's lymphoma, Hodgkin's disease, non-Hodgkin lymphoma, extranodal NK/T-cell lymphoma, post-transplant lymphoproliferative diseases), nasopharyngeal carcinoma, hydroa vacciniforme, chronic active EBV disease, and many other conditions. Some of these disorders are reported especially in Asian and Latin-American populations, suggesting a genetic susceptibility to these diseases.
This Research Topic aims to explore the diverse manifestations of HTLV-1 and EBV-associated disorders focusing on the pathogenesis, clinical manifestations, and treatments. This topic will enlighten the mechanisms of interaction between HTLV-1 and EBV with the host immune system, the clinical features observed in infected patients, and will give an overview of the up-to-date treatments available and under development for these disorders.
Type of manuscript: original research or review articles
Topics may include but are not limited to:
- Epidemiology of HTLV-1 and EBV-associated disorders
- Pathogenesis of adult T-cell leukemia/lymphoma, HTLV-1-associated myelopathy/Tropical
spastic paraparesis, and infective dermatitis
- Clinical manifestations, treatments, and prognostic characteristics of ATLL
- Cost-effectiveness of HTLV-1 prevention in endemic countries
Keywords: Human T-lymphotropic virus 1, Epstein-Barr virus infection, ATLL, HTLV-I-Associated Myelopathy-Tropical Spastic Paraparesis, Hydroa vacciniforme, Epidemiology, Biology, Therapeutics
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
